AQEMIA is a drug invention company developing novel molecules to address unmet medical needs. Its proprietary QEMI platform combines over a decade of physics-based research with state-of-the-art generative AI, enabling the rapid design of drug candidates without relying on experimental training data.

By leveraging its unique fast physics engine, the company reconciles speed and precision in molecular design, unlocking large-scale exploration of previously inaccessible chemical space. Aqemia’s portfolio spans oncology, immunology and neurology, and includes both wholly owned programs and partnered programs with leading pharmaceutical companies, such as a multi-year, $150M strategic collaboration with Sanofi.

The company’s most advanced preclinical programs are currently undergoing in vivo optimization, demonstrating superior efficacy in animal models.

Headquartered in Paris with an office in London, AQEMIA employs around 70 people and has raised over $100 million since its inception.